How will increasing our knowledge of the head and neck cancer cells’ secretome benefit head and neck squamous cell carcinoma patients?

Objective To examine the prevalence and predictors of patient-reported barriers to care among survivors of head and neck squamous cell carcinoma and the association with health-related quality of life (HRQOL) outcomes. Study Design Retrospective cohort study. Setting Outpatient oncology clinic at an academic tertiary care center. Methods Data were obtained from the UNC Health Registry/Cancer Survivorship Cohort. Barriers to care included self-reported delays in care and inability to obtain needed care due to cost. HRQOL was measured with validated questionnaires: general (PROMIS) and cancer specific (FACT-GP). Results The sample included 202 patients with head and neck squamous cell carcinoma with a mean age of 59.6 years (SD, 10.0). Eighty-two percent were male and 87% were White. Sixty-two patients (31%) reported at least 1 barrier to care. Significant predictors of a barrier to care in unadjusted analysis included age ≤60 years ( P = .007), female sex ( P = .020), being unmarried ( P = .016), being uninsured ( P = .047), and Medicaid insurance ( P = .022). Patients reporting barriers to care had significantly worse physical and mental HRQOL on the PROMIS questionnaires ( P < .001 and P = .002, respectively) and lower cancer-specific HRQOL on the FACT-GP questionnaire ( P < .001), which persisted across physical, social, emotional, and functional domains. There was no difference in 5-year OS (75.3% vs 84.1%, P = .177) or 5-year CSS (81.6% vs 85.4%, P = .542) in patients with and without barriers to care. Conclusion Delay- and affordability-related barriers are common among survivors of head and neck cancer and appear to be associated with significantly worse HRQOL outcomes. Certain sociodemographic groups appear to be more at risk of patient-reported barriers to care.

Download Full-text

Should age affect our treatment decisions for head and neck cancer?

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.5564 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 5564-5564

Author(s):

Estrella M. Carballido ◽

Jon N Burton ◽

Miguel Ricardo Pelayo ◽

Judith C McCaffrey ◽

Tapan Padhya ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Comprehensive Cancer Center ◽

Significant Difference

5564 Background: Current opinion suggests elderly patients (pts) with head and neck cancer, those 65 or older, do not tolerate surgery, chemotherapy, or radiation as well as their younger counterparts. If this holds true, elderly pts may not be offered standard treatments to prevent assumed complications. Methods: A retrospective cohort study at our comprehensive cancer center was conducted of newly diagnosed pts with head and neck squamous cell carcinoma to explore differences in treatment-related complications between older and younger groups. We included data from the first 199 eligible pts (99 younger than 65 year old and 100 older than 65) evaluated between April 2009 and June 2010. Results: 79% of pts receiving treatment were male with a mean age of 54.9 and 71.6 years for the younger and older groups respectively. The older group had significantly more comorbidities (p < 0.001). The majority of older pts presented with oral cavity tumors (46%) while the oropharynx was the predominant site in the younger group (45%). 55% of younger and 49% of older pts presented with stage 4 disease across all sites. A total of 51 pts were p16 positive with no statistical differences between the groups. Surgery was the initial treatment for 57% of older pts (p < 0.008) while 46% of younger pts received concurrent chemotherapy and radiation as the primary treatment (p < 0.008). There was no statistically significant difference in surgical or radiation complications between the groups. Although most pts receiving chemotherapy experienced complications, older pts had slightly more (93% vs. 78%; p<0.031). The mean survival was 24.8 months with no statistical difference between groups. Significantly more pts in the older group, at last follow-up, were disease free (p < 0.012). Conclusions: The treatment of elderly pts with head and neck squamous cell carcinoma in our experience was congruent with that of younger pts. Elderly pts did not suffer more complications with surgery or radiation, however chemotherapy produced somewhat more complications in the elderly pts. Elderly pts did display less evidence of disease on follow-up. Age is always a consideration when treating individuals, but should not preclude the curative standard.

Download Full-text

Correlation Between Subjective Evaluation of Symptoms and Objective Findings in Early Recurrent Head and Neck Squamous Cell CarcinomaHead and Neck Cancer Evaluation and Findings

JAMA Otolaryngology–Head & Neck Surgery ◽

10.1001/jamaoto.2013.3289 ◽

2013 ◽

pp. 1 ◽

Cited By ~ 1

Author(s):

Lluís Nisa

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Subjective Evaluation ◽

Neck Squamous Cell Carcinoma ◽

Recurrent Head

Download Full-text

Radiosensitivity of Head and Neck Cancer Cells In Vitro: A 96-Well Plate Clonogenic Cell Assay for Squamous Cell Carcinoma

Archives of Otolaryngology - Head and Neck Surgery ◽

10.1001/archotol.1988.01860160071024 ◽

1988 ◽

Vol 114 (4) ◽

pp. 427-431 ◽

Cited By ~ 24

Author(s):

R. Grenman ◽

D. Burk ◽

E. Virolainen ◽

J. G. Wagner ◽

A. S. Lichter ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Cancer Cells ◽

Neck Cancer ◽

Squamous Cell ◽

Cell Assay ◽

Clonogenic Cell

Download Full-text

Human papillomavirus detection in head and neck squamous cell carcinoma in Turkey.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e17538 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e17538-e17538

Author(s):

Yasemin Kemal ◽

Ozgur Kemal ◽

Mehmet Kefeli ◽

Ayse Bel ◽

Nilgun Sahin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Large Scale ◽

Neck Squamous Cell Carcinoma ◽

Smoking History ◽

Cancer Tissue

e17538 Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide. In Turkey, 5538 new cases and 2340 deaths from head and neck cancer are estimated to occur every year. Tobacco and alcohol are the most important etiological risk factors but in the past three decads tobacco usage is decreased and Human Papilloma Virus (HPV) has changed HNSCC epidemiology. Many new reports suggests that almost 25% of all cases of HNSCC are related to HPV. But its prevelans shows a wide variation among different populations.Today in Turkey HPV positivity in HNSCC is currently not known and this retrospective study aimed to to evaluate the HPV infection in our HNSCC patients. Methods: We included 125 HNSCC patients diagnosed and treated in our hospital beween January 2010 and December 2016. Oral cavity, oropharyngeal, laryngeal and hypopharyngeal cancers were included. Nasopharyngeal and salivary gland cancers were exculuded. Head and neck cancer tissue samples fixed using 10% Neutral Buffered Formalin and embedded blocks were used. From an initial evaluation of 125 patients records 77 of the paients blocks could be adequate for the HPV testing. Detection and genotyping of HPV genotypes were done using a polymerase chain reaction (PCR) protocol. Results: PCR amplification was succesful in 61 of 77 patients. Among the 61 HNSCC patients only 3 patients were HPV positive(4.9 %). HPV 16 subtype was detected in one patient who was 70 years old male, stage III laryngeal cancer with a smoking history. The subtypes detected in other two patients were different from 16 and 18. One of these patients was 42 years old nonsmoker female stage IVa hypopharyngeal cancer and the other one was 56 years old smoker male with stage II oropharyngeal cancer. Conclusions: In Turkey, this is the first study that evaluated HPV positivity in HNSCC. Our results suggest a low prevelance of HPV in Turkish HNSCC patients; large scale population based studies are needed to confirm our findings.

Download Full-text

Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki )

International Journal of Cancer ◽

10.1002/1097-0215(200002)9999:9999<::aid-ijc1142>3.0.co;2-u ◽

2001 ◽

Vol 91 (6) ◽

pp. 840-845 ◽

Cited By ~ 25

Author(s):

Olivier Pradier ◽

Margret Rave-Fr�nk ◽

J�rg Lehmann ◽

Eva L�cke ◽

Oliver Boghun ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Cancer Cells ◽

Neck Cancer ◽

Squamous Cell ◽

Human Head ◽

Cervical Squamous Cell Carcinoma ◽

Carcinoma Cells

Download Full-text

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges

Frontiers in Oncology ◽

10.3389/fonc.2020.608772 ◽

2021 ◽

Vol 10 ◽

Author(s):

Jack M. Qian ◽

Jonathan D. Schoenfeld

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Clinical Evidence ◽

Locally Advanced ◽

Neck Squamous Cell Carcinoma ◽

Current Evidence

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment over the past decade. However, although the immune landscape suggests a strong rationale for the use of these agents in patients with head and neck squamous cell carcinoma, the available clinical evidence indicates that most patients currently do not respond to ICI monotherapy. Radiotherapy is a primary treatment modality for many patients with locally advanced head and neck cancer. While ionizing radiation traditionally has been thought to act in a purely cytotoxic fashion, a growing body of preclinical studies have demonstrated additional profound immunomodulatory effects. Consequently, there has been a surge of interest in the potential synergy between radiotherapy and immunotherapy, both the potential for radiotherapy to augment the systemic anti-tumor immune response and the potential for immunotherapy to improve in-field tumor response to radiation. In this review, we summarize the current preclinical and clinical evidence for radioimmunotherapy, with a particular focus on studies directly relevant to head and neck squamous cell carcinoma, as well as existing challenges and future directions for this emerging field.

Download Full-text